ANTURANE Drug Patent Profile
✉ Email this page to a colleague
When do Anturane patents expire, and when can generic versions of Anturane launch?
Anturane is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in ANTURANE is sulfinpyrazone. There are four drug master file entries for this compound. Additional details are available on the sulfinpyrazone profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ANTURANE?
- What are the global sales for ANTURANE?
- What is Average Wholesale Price for ANTURANE?
Summary for ANTURANE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 99 |
| Patent Applications: | 3,916 |
| DailyMed Link: | ANTURANE at DailyMed |
US Patents and Regulatory Information for ANTURANE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | ANTURANE | sulfinpyrazone | CAPSULE;ORAL | 011556-004 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | ANTURANE | sulfinpyrazone | TABLET;ORAL | 011556-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
